ESR1 Mutations are the Leading Cause of Primary Treatment Resistance in HR+ mBC
ESR1 gene codes for estrogen receptor alpha (ERα), and mutations in its ligand-binding domain trigger constant activation of the receptor, leading to excessive downstream signalling.
Introducing the Asuragen AmplideX® Nanopore Carrier Plus Kit* – a revolutionary solution for carrier screening for challenging hard-to-read genes, leveraging long-read sequencing technology to provide unparalleled insights into genetic conditions. Expanded prenatal screening protocols traditionally require multiple methods to ensure full coverage of genes of interest.
Asuragen’s Precision Oncology Solutions.
Revolutionising Precision Oncology with QuantideX®: Where Sensitivity Meets Scalability
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
How is your lab performing FMR1 gene testing?
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Cystic fibrosis (CF) is a life-limiting, autosomal recessive disease caused by the presence of pathogenic alterations in the CFTR gene.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
With the AmplideX Trio, you can use one shared workflow to analyze CFTR, SMN1/2, and FMR1. This saves your lab tech time, simplifies training, and reduces consumables used.
Products are for professional/laboratory use only.
The AmplideX® PCR/CE SMN1/2 Plus Kit* is an in vitro nucleic acid amplification kit intended to aid in the screening of carriers for and diagnosis of spinal muscular atrophy (SMA).
Products are for professional/laboratory use only.
Webinar Invitation:
Looking Beyond Copy Number:
Broad SMN1 and SMN2 profiling in under four hours with the AmplideX® PCR/CE SMN1/2 Plus Kit (RUO)
Products are for professional/laboratory use only. Abacus dx is pleased to announce the launch of the latest assay from the Asuragen spinal muscular atrophy (SMA) portfolio – AmplideX® PCR/CE SMN1/2 Plus Kit*.